While the results are promising, future investigation of the potential of PRL2 inhibition as a therapeutic strategy for AML and other cancers will require investigation and validation of the efficacy of the approach during both early-stage development and progression, as demonstrated in the current study, and also the impact of PRL2 inhibition of late-stage disease. Here, PTP4A2 is linked to cancer.